In the quarter ended June 2025 (Q1FY26), Sun Pharma‘s stock’s consolidated net profit fell 20% to ₹2,279 crore, dented by a one-time exceptional charge. It posted a net profit of ₹2,835 crore in the same period last year. Sequentially, the profit rose 6% from ₹2150 crore in the March quarter.
Driven by strong growth across key markets, including India, the US, and the rest of world, its consolidated revenue, however, rose 9% to ₹13,851 crore in the June 2025 quarter from ₹12,653 crore in the same period in Q1FY25.
Sun Pharma’s earnings before interest, tax, depreciation and amortisation (EBITDA) for the quarter increased by 19.2% from last year to ₹4,302 crore. EBITDA margin for the quarter expanded by 250 basis points to 31% from 28.5% last year.
Highlights of Q1FY26 consolidated financials*
- Gross sales at Rs 13,786.1 crore, growth of 10.1%
- India formulation sales at Rs 4,721.1 crore, up 13.9%
- US formulation sales at US$ 473 million, up 1.4%
- Global innovative medicines sales at US$ 311 million, up 16.9%, accounting for 19.3% of Q1FY26 sales
- Emerging markets formulation sales at US$ 298 million, up 5.1%
- Rest of world formulation sales at US$ 219 million, up 15.5%
- R&D investments at Rs. 902.9 crore or 6.5% of sales compared to Rs 794 crore for Q1FY25
- EBITDA at Rs 4,301.7 crore (including other operating revenues), up 19.2%, with resulting EBITDA margin of 31.1%
- Profit before exceptional items and tax was Rs 3,990.8 crore up 16.6%
- Adjusted net profit (excluding the exceptional items) for Q1FY26 was Rs. 2,996.1 crore, up 5.7%. Reported net profit for Q1FY26 was Rs. 2,278.6 crore compared to Rs. 2835.6 crore during Q1FY25
(*Growth measured vs same period last financial year)
Dilip Shanghvi, chairman and managing director, said, “Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The US launch of Leqselvi represents an important step forward, offering a new treatment option for patients with severe alopecia areata. Leqselvi augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business.”
